Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Q2 2023 · 10-Q
Revenue$6.60B$6.60B+5.4% vs Q2 2022 Net Income$1.05B$1.05B−8.7% vs Q2 2022 EPS Diluted$0.83$0.83−8.8% vs Q2 2022 Operating Income$1,665,000,000−17.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,199,000,000+32.5% Margins · derivedOperating margin25.2%−7.2 pt vs Q2 2022
Net margin15.8%−2.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 4, 2023 · 35 d after period end